Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crinetics Pharmaceuticals Inc
(NQ:
CRNX
)
53.15
-0.09 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Crinetics Pharmaceuticals Inc
< Previous
1
2
Next >
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
October 11, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END
Via
FinancialNewsMedia
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
September 20, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Near the Top of Equities by Percentage Gain on 9/11
September 11, 2023
Via
Investor Brand Network
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
September 12, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 11, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
September 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
June 21, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics to Highlight Broad Pipeline at ENDO 2023
June 09, 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
February 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
November 28, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
October 13, 2022
Topline results for PATHFNDR-1 study expected in Q3 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
October 06, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
October 03, 2022
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.